Quest Diagnostics Inc Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Quest Diagnostics Inc (DGX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $34.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $34.00M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $35.00M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $33.00M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $32.00M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $34.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $35.00M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $33.00M 10-K · filed 2025-02-20 | |
| 2022-12-31 | $32.00M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $32.00M 10-K · filed 2023-02-21 | |
| 2020-12-31 | $47.00M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $35.00M 10-K · filed 2021-02-22 | |
| 2018-12-31 | $38.00M 10-K · filed 2020-02-20 | |
| 2017-12-31 | $41.00M 10-K · filed 2019-02-21 | |
| 2016-12-31 | $58.00M 10-K · filed 2018-02-23 | |
| 2015-12-31 | $49.00M 10-K · filed 2017-02-22 | |
| 2014-12-31 | $42.00M 10-K · filed 2016-02-26 | |
| 2013-12-31 | $43.00M 10-K · filed 2015-02-24 | |
| 2012-12-31 | $58.00M 10-K · filed 2014-02-18 | $58.25M 10-K · filed 2013-02-27 |
| 2011-12-31 | $72.26M 10-K · filed 2013-02-27 | |
| 2010-12-31 | $73.66M 10-K · filed 2012-02-16 | |
| 2009-12-31 | $72.25M 10-K · filed 2011-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |